Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma.

Trial Profile

Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Tisagenlecleucel-T (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Leukaemia; Lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2017 Results of this and other trials (NCT01747486 and NCT01626495) published in the Blood
    • 06 Dec 2016 Results assessing cellular kinetics of chimeric antigen receptor T cells (CTL019) from this and other two studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 31 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top